Comparative Pharmacology
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus BYSTOLIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus BYSTOLIC.
ACEBUTOLOL HYDROCHLORIDE vs BYSTOLIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker) with intrinsic sympathomimetic activity (ISA). Competitively blocks catecholamine binding at cardiac beta-1 receptors, reducing heart rate, myocardial contractility, and blood pressure. ISA provides mild beta-receptor stimulation, decreasing the extent of resting bradycardia and lipid changes.
Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.
Dose: 200-800 mg/day orally in 1-2 divided doses. Initially 200 mg twice daily; may increase to 400 mg twice daily as needed.
Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.
None Documented
None Documented
3-4 hours for acebutolol; 8-13 hours for diacetolol (active metabolite); clinically significant in renal impairment
Terminal elimination half-life: 10-12 hours; allows once-daily dosing in most patients; steady-state achieved in 3-5 days
Renal: 30-40% as unchanged drug and 50-60% as diacetolol; fecal: ~10%
Renal: 38% unchanged; hepatic metabolism: extensive; fecal: minor; total renal clearance accounts for 30-50% of dose
Category C
Category C
Beta Blocker
Beta Blocker